Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-0120 in Hyperuricemia and Gout
NCT03923868Phase 2Completed
- Sponsor
- InventisBio
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darbinurad in hyperuricemia and gout (2 arms), sponsored by InventisBio. Primary endpoints: The number of subjects with treatment-related adverse events, Time to observed Cmax (Tmax) for D-0120 and 2 more. Started Apr 2019; status: completed.
02
Drugs
darbinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT03923868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923868.